RWM
CLBT icon

Ritholtz Wealth Management’s Cellebrite CLBT Stock Holding History

Ritholtz Wealth Management’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,605
Closed -$42K – 601
2022
Q3 		$42K Buy
+10,605
New +$53.2K ﹤0.01% 706

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
LSCM
Light Street Capital Management Palo Alto, California $903M AUM 113.12% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
CC
Crosslink Capital Menlo Park, California $1.35B AUM 35.86% 1-Year Est. Return
IP
Isomer Partners New York $74.3M AUM 23.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MCM
Makena Capital Management Menlo Park, California $952M AUM 13.93% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Ritholtz Wealth Management's CLBT Position: Q4 2022 in Review

Ritholtz Wealth Management sold out of Cellebrite (CLBT) in Q4 2022, closing a stake of 10,605 shares — an estimated $42K sold.

Ritholtz Wealth Management first reported a position in CLBT in Q3 2022 and held it in 1 quarter. The position peaked at $42K in Q3 2022. 53 funds tracked by Wall St. Rank hold CLBT as of Q4 2022.

  • Ritholtz Wealth Management reported no remaining Cellebrite position as of Q4 2022 after selling out during the quarter.
  • Ritholtz Wealth Management sold 10,605 Cellebrite shares in Q4 2022, an estimated $42K.
  • Ritholtz Wealth Management first reported a position in Cellebrite in Q3 2022 and held it in 1 quarter.
  • Ritholtz Wealth Management's Cellebrite position peaked at $42K in Q3 2022.
  • 53 funds tracked by Wall St. Rank held Cellebrite as of Q4 2022.

Based on Ritholtz Wealth Management's 13F filing for Q4 2022, filed 19 Jan 2023.